AI In Drug Discovery Market Size, Share, Growth Analysis, By Component (Software, Services), By Technology (Machine Learning, Deep Learning), By Application (Target Identification, Molecule Screening), By Region - Industry Forecast 2025-2032

Huge spending on healthcare technology and strategic collaborations between tech leaders and pharmaceutical firms have made North America lead the market with a 57.7% share in 2023 of AI in drug discovery. Innovation and the advance of AI-driven solutions are further facilitated by the region's best research institutes and a favorable regulatory framework. North American firms increasingly employ AI to optimize drug discovery operations and increase productivity, reduce development costs, and accelerate the launch of new therapies. Customized medicine is finally becoming a pressing need and the advancement of AI capabilities to solve challenges in drug development as well are two more factors that drive this trend to expand further. 

Contrarily, the AI in drug discovery market in Europe is expected to grow significantly over the forecast period. Europe emerges as a prime player in the market for AI in drug discovery, largely attributed to significant contributions from countries such as the UK and Germany. The region has sturdy research infrastructure that supports AI integration in healthcare, with beneficial regulatory frameworks in place. European companies are leading the pack in the adoption of AI in drug discovery, focusing on advanced analytics and personalized medicine to enhance the drug development process. This is being propelled by collaboration between government organizations, businesses, and academia.